Recommendations about add-on reimbursement for medical devices in France in June 2022

27

Jul 2022

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in June 2022. Nineteen recommendations were published in relation to the registration, modification of registration conditions, and renewal of registration for devices in the List of reimbursable products and services (LPPR). Opinions concern cardiovascular, interventional radiology, orthopedic, neurovascular and neuromodulation, ophthalmology, as well as medical aids.

The first step in the assessment is the clinical (actual) benefit (SA), which can be either sufficient or insufficient. This step determines the insertion into the LPPR list. If sufficient, the clinical added value (ASA) is graded on a scale from I (major) to V (absent) for claimed indications, which supports the pricing decisions.

Recommendations for cardiovascular devices:

  • Edge-to-edge mitral repair clip MITRACLIP G4-XTW by ABBOTT (application for registration; sufficient actual benefit; level V of clinical added value)
  • Portable external cardiac defibrillator LIFEVEST 4000 by ZOLL MEDICAL (application for modification of registration conditions; insufficient)
  • Coronary endoprosthesis coated with biolimus BIOFREEDOM by BIOSENSORS (application for modification and renewal of registration; sufficient actual benefit; level V of clinical added value)

Recommendations for interventional radiology devices:

  • Radiofrequency needle electrodes LEVEEN by BOSTON SCIENTIFIC (application for modification of registration conditions; sufficient actual benefit; level II, III, or IV of clinical added value depending on the considered indications and comparators

Recommendations for neurovascular and neuromodulation devices:

  • Stent retriever EMBOTRAP III by JOHNSON & JOHNSON (application for modification of registration conditions; sufficient actual benefit; level V of clinical added value)
  • Stent retriever EMBOTRAP II by JOHNSON & JOHNSON (application for modification of registration conditions; sufficient actual benefit; level V of clinical added value)
  • Intrathoracic phrenic stimulator ATROSTIM by NEURORESP (application for renewal of registration; sufficient actual benefit; level II of clinical added value)

Recommendations for orthopedic devices:

  • Highly cross-linked polyethylene insert LONGEVITY by ZIMMER BIOMET (application for renewal of registration; sufficient actual benefit; level IV or V of clinical added value depending on the considered comparators)
  • Vertebral body stent system VERTEBRAL BODY STENT by JOHNSON & JOHNSON (application for registration; sufficient actual benefit; level IV or V of clinical added value depending on the considered comparators
  • Highly cross-linked polyethylene insert PLASMAFIT VITELENE by B.BRAUN MEDICAL (application for renewal of registration; sufficient actual benefit; level V of clinical added value)

Recommendations for ophthalmological devices:

  • Viro-inactivated amniotic membrane VISIO AMTRIX by TBF - TISSUE ENGINEERING (application for registration; insufficient actual benefit)

Recommendations for medical aids:

  • Modular ankle joint for lower limb orthosis NEURO SWING by FIOR & GENTZ (application for registration; sufficient actual benefit; level V of clinical added value)
  • Electric breast pump for individual use MATERNOV, ELECTRIC BREAST PUMP by MAJORELLE LABORATORIES (application for registration; insufficient actual benefit)
  • Telethesis: remote control adapted to the handicap to allow the control of the electric and electronic environment of the person in the situation of handicap GEWA ONE by CREE (application for registration; sufficient actual benefit; level V of clinical added value)
  • Hydraulic polycentric hip joint HELIX 3D 7E10 by OTTO BOCK (application for modification and renewal of registration; sufficient actual benefit; level IV of clinical added value)
  • Myoelectric elbow for external prosthesis of the upper limb DYNAMICARM by OTTO BOCK (application for registration; sufficient actual benefit; level IV of clinical added value)
  • Adult therapeutic shoes for prolonged use AD 8001 by ADOUR PIED CONFORT FRANCIS LAVIGNE (application for registration; sufficient actual benefit; level V of clinical added value)
  • Adult therapeutic shoes for prolonged use AD 8000 by ADOUR PIED CONFORT FRANCIS LAVIGNE (application for registration; sufficient actual benefit; level V of clinical added value)
  • Secure pill dispenser in pharmacies via a web application MEDIPAC by MEDISSIMO (application for registration; insufficient actual benefit)

See the details in French here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news

07

Jun 2023

In May 2023, the National Institute for Health and Care Excellence (NICE) published one new Interventional Procedure Guidance (intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure from high spinal cord injuries), two new Diagnostic Guidance (MRI fusion biopsy systems for diagnosing prostate cancer, automated ankle-brachial pressure index measurement devices to detect peripheral arterial disease), and three new Health Technology Evaluations (Digitally enabled therapies for adults with anxiety disorders / with depression, and point-of-care tests for urinary tract infections). Also, four clinical guidelines were updated.

Read more

06

Jun 2023

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in May 2023. Twenty-one recommendations were published in relation to the registration, modification of registration conditions, and renewal of registration for devices in the List of reimbursable products and services (LPPR). Opinions concern cardiovascular and peripheral vascular, endocrine, ENT, gastrointestinal, and orthopedic devices, as well as medical aids.

Read more

01

Jun 2023

On May 23, 2023, the Ministry of Health and Prevention published an Order in the Official Journal of the French Republic setting the tariffs for the medical telemonitoring activities covered by social health insurance in the context of the new framework. The tariffs will differ whether they bring an organizational or clinical (improvement in quality of life, morbidity, or mortality) benefit.

Read more

30

May 2023

On April 5, 2023, the Innovation Committee at the Federal Joint Committee (G-BA) announced the selection of thirty-five applications for Innovation Funding of healthcare research projects were accepted. A total of 231 applications were received in response to the funding announcement of June 27, 2022 (changed on September 20, 2022), and thirty-five of them were accepted.

Read more

29

May 2023

On May 17, 2023, the Ministry of Health and Prevention published the 2023-2027 Digital Health Roadmap. The new roadmap specifies the priorities and the projects to be carried out by 2027. One of the key objectives is to support the implementation and extension of telemonitoring to more chronic pathologies.

Read more